Sexual health products tops in DTC-driven web traffic

Share this article:
NuvaRing and Latisse lead the pack in DTC-driven traffic to their brand.com sites, according to Manhattan Research.

The research firm's ePharma Consumer survey found that Merck Contraceptive NuvaRing jumped five spots to take the top spot for ad-driven traffic, while Allergan's eyelash-extender, Latisse, launched last year, placed second.  
Sexual health products dominated the top 10. Latisse was followed by Cialis, Boniva, Abilify, Gardasil, Yaz, Viagra, Levitra and Lunesta.

“These are things where talking to friends and family or doctors might be awkward, so they want to research it on their own,” said VP research Meredith Ressi, “and especially with the oral contraceptive category, that's a much younger segment and one that's very active online.”

Also common to the top 10 was full incorporation of the website into the broader ad campaign. “Latisse especially integrated the URL into their campaign,” said Ressi, noting that ads pointed viewers to the site for before and after photos of Brooke Shields' lashes, and to submit their own.

The study results will be the topic of a Manhattan Research webinar Thursday.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.